Stockreport

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer [Yahoo! Finance]

Elevation Oncology, Inc. - Common stock  (ELEV) 
PDF -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address [Read more]